Press Releases

Date Title and Summary
Toggle Summary Ionis Pharmaceuticals Announces Publication in Nature Biotechnology of a Novel Mechanism of Action for Antisense Drugs That Significantly Expands Therapeutic Opportunities
Toggle Summary Ionis Pharmaceuticals Reports Positive Clinical Data on IONIS-TTR Rx at the XV International Symposium on Amyloidosis
Toggle Summary Akcea Therapeutics Announces Launch of IN-FOCUS, a Research Study to Assess Impact of Familial Chylomicronemia Syndrome
Toggle Summary Akcea Announces Publication of Positive Volanesorsen Clinical Data Showing Reduced Triglycerides and Improved Insulin Sensitivity in Patients with High Triglycerides and Type 2 Diabetes
Toggle Summary Ionis Pharmaceuticals to Host R&D Day
Toggle Summary Ionis Pharmaceuticals Provides Update on IONIS-TTR Rx Program
Toggle Summary Ionis Pharmaceuticals and MD Anderson Form Strategic Alliance to Advance Novel Cancer Therapeutics
Toggle Summary Akcea Therapeutics Announces Completion of Enrollment in Phase 3 COMPASS Trial of Volanesorsen
Toggle Summary Ionis Pharmaceuticals Provides Corporate Update at 2016 Annual Meeting of Stockholders
Toggle Summary Ionis Reports Financial Results and Highlights for First Quarter 2016
Toggle Summary Ionis Pharmaceuticals and Kastle Therapeutics Announce Acquisition of KYNAMRO®
Toggle Summary Webcast Alert: Ionis Pharmaceuticals' First Quarter 2016 Financial Results Conference Call
Toggle Summary Ionis Pharmaceuticals Reports Data Update from Nusinersen Phase 2 Study in Infants with Spinal Muscular Atrophy and Reviews Neurological Disease Franchise
Toggle Summary Ionis Pharmaceuticals Highlights Antisense Drugs to Treat Neurological Diseases at the AAN Meeting
Toggle Summary Ionis Pharmaceuticals Provides Update on IONIS-TTRRX Program
Toggle Summary Akcea Therapeutics to Present at 15th Annual Needham Healthcare Conference
Toggle Summary Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
Toggle Summary Ionis Pharmaceuticals Advances Nusinersen in the Ongoing SHINE Study in Patients with SMA
Toggle Summary Akcea Therapeutics Supports World Lipodystrophy Day
Toggle Summary Ionis Pharmaceuticals and Merck Receive Positive Verdict on Gilead HCV Drug Patent Case
Toggle Summary Akcea Therapeutics to Present at Cowen and Company 36th Annual Health Care Conference
Toggle Summary Ionis Pharmaceuticals Supports Rare Disease Day
Toggle Summary Ionis' 2015 Financial Results Outperform Projections
Toggle Summary Ionis Pharmaceuticals to Hold 2015 Financial Results Conference Call
Toggle Summary Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
Toggle Summary Akcea Therapeutics Appoints Louis St. L. O'Dea as Chief Medical Officer
Toggle Summary Ionis Pharmaceuticals Announces that GSK has Initiated a Phase 1 Study of IONIS-HBV-L Rx
Toggle Summary Ionis Pharmaceuticals Completes Target Enrollment for Nusinersen Phase 3 Study, CHERISH, in Children with Spinal Muscular Atrophy
Toggle Summary Ionis Pharmaceuticals Revises 2015 Financial Guidance and Provides Pipeline Update in Conjunction with J.P. Morgan Conference
Toggle Summary Ionis Pharmaceuticals Receives Orphan Drug Designation from the US FDA for IONIS-HTT Rx for the Treatment of Patients with Huntington's Disease
Toggle Summary Ionis Pharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference
Toggle Summary Ionis Pharmaceuticals Earns $5 Million Milestone Payment from Biogen for Advancing a New Program Under Its Broad Neurology Strategic Collaboration
Toggle Summary Isis Pharmaceuticals Changes Name to Ionis Pharmaceuticals
Toggle Summary Isis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Phase 2 Study of ISIS-TTR Rx in Patients with TTR Cardiomyopathy Amyloidosis
Toggle Summary Isis Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Study of ISIS-SOD1 Rx in Patients With ALS
Toggle Summary Isis Pharmaceuticals Earns $2.8M for Advancing ISIS-DMPK-2.5 Rx in Patients with Myotonic Dystrophy Type I
Toggle Summary Isis Reports Financial Results and Highlights for Third Quarter 2015
Toggle Summary Isis Pharmaceuticals Reports Positive Clinical Data From Lp(a) Lowering Drugs
Toggle Summary Isis Pharmaceuticals to Present at Upcoming Investor Conferences
Toggle Summary Isis Pharmaceuticals and Akcea Therapeutics Announce Start of Phase 3 Study of Volanesorsen in Patients with Familial Partial Lipodystrophy
Toggle Summary Isis Pharmaceuticals to Host Webcast to Review ISIS-APO(a) Rx and ISIS-APO(a)-L Rx Data Presented at American Heart Association Scientific Sessions
Toggle Summary Isis Pharmaceuticals Reports an Update on ISIS-TTR Rx, Including Positive Data from Multiple Clinical Studies, Presented Today at the EC-ATTR Meeting
Toggle Summary Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis
Toggle Summary Isis Pharmaceuticals to Host Webcast to Review ISIS-TTR Rx Data Presented at 1st European Congress of Hereditary ATTR Amyloidosis and Provide Phase 3 Development Plan Update
Toggle Summary Isis Pharmaceuticals Earns $5 Million from GSK for Initiation of Phase 1 Study of ISIS-GSK4-L Rx
Toggle Summary Webcast Alert: Isis Pharmaceuticals' Third Quarter 2015 Financial Results Conference Call
Toggle Summary Isis Pharmaceuticals Initiates SHINE Study to Provide ISIS-SMN Rx for Patients With SMA Who Have Completed the Phase 3 ENDEAR and CHERISH Studies
Toggle Summary Isis Pharmaceuticals' Collaboration to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases with AstraZeneca Receives HSR Clearance
Toggle Summary Isis Pharmaceuticals to Present at Upcoming Investor Conferences
Toggle Summary Isis Reports Financial Results and Highlights for Second Quarter 2015
Toggle Summary Isis Reports Positive Data from KYNAMRO® (mipomersen sodium) FOCUS FH Phase 3 Study in Patients with Severe Heterozygous Familial Hypercholesterolemia
Toggle Summary AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases
Toggle Summary Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine
Toggle Summary Webcast Alert: Isis Pharmaceuticals' Second Quarter 2015 Financial Results Conference Call
Toggle Summary Isis Pharmaceuticals Reports Data From ISIS-TTR Rx in Patients With Transthyretin Amyloid-Related Cardiomyopathy
Toggle Summary Positive Clinical Data From Lp(a) Lowering Drug ISIS-APO(a) Rx Published in The Lancet
Toggle Summary Isis Pharmaceuticals Initiates Clinical Study of ISIS-HTT Rx in Patients With Huntington's Disease
Toggle Summary Isis Pharmaceuticals Earns $2.15M for Advancing ISIS-SMN Rx in Children With Spinal Muscular Atrophy
Toggle Summary Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome
Toggle Summary Webcast Alert: Corporate Presentation at the 2015 Isis Pharmaceuticals Annual Stockholder Meeting
Toggle Summary Isis Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index
Toggle Summary Isis Pharmaceuticals Reports Data from ISIS-SMN Rx in Children with Spinal Muscular Atrophy
Toggle Summary Isis Pharmaceuticals to Present a General Corporate Update at its 2015 Annual Meeting of Stockholders and Open House
Toggle Summary Isis Pharmaceuticals Reports Data From ISIS-SMN Rx Phase 2 Study in Infants With Spinal Muscular Atrophy
Toggle Summary Isis Pharmaceuticals to Host Webcast to Discuss Data From ISIS-SMN Rx Phase 2 Study in Infants With Spinal Muscular Atrophy
Toggle Summary Isis Pharmaceuticals' License Agreement With Bayer for ISIS-FXI Rx Receives Hart-Scott-Rodino Approval
Toggle Summary Isis Pharmaceuticals to Present at the Goldman Sachs 36th Annual Global Healthcare Conference
Toggle Summary Webcast Alert: Akcea Therapeutics Conference Call
Toggle Summary Isis Reports Financial Results and Highlights for First Quarter 2015
Toggle Summary Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis
Toggle Summary Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen
Toggle Summary Webcast Alert: Isis Pharmaceuticals' First Quarter 2015 Financial Results Conference Call
Toggle Summary Isis Pharmaceuticals Reports Positive Data From ISIS-TTR Rx in Patients With TTR Amyloidosis
Toggle Summary Isis Pharmaceuticals to Present at Upcoming Investor Conferences
Toggle Summary Isis Pharmaceuticals Reports Positive Phase 1 Data on Isis-ANGPTL3Rx
Toggle Summary Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy
Toggle Summary Isis Pharmaceuticals Earns $15 Million From GSK for Advancing ISIS-TTR Rx
Toggle Summary Isis Reports Financial Results and Highlights for 2014
Toggle Summary ISIS Pharmaceuticals Reports Positive Phase 1 Data Demonstrating ISIS-PKK Rx Produces Significant Reductions in Prekallikrein Levels
Toggle Summary Webcast Alert: Isis Pharmaceuticals' 2014 Financial Results and Highlights Conference Call
Toggle Summary Isis Pharmaceuticals Earns $5 Million Milestone Payment From Biogen Idec
Toggle Summary Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen Idec for Advancing New Drug Into Development to Treat a Neurodegenerative Disease
Toggle Summary Isis Pharmaceuticals to Present at Upcoming Investor Conferences
Toggle Summary Isis Pharmaceuticals Reports Data From Phase 2 Study of ISIS-PTP1B Rx in Patients With Type 2 Diabetes
Toggle Summary Isis Pharmaceuticals Earns $7M for Advancing ISIS-SMN Rx in Children With Spinal Muscular Atrophy
Toggle Summary Alnylam and Isis Form New Agreement, Extending Decade-Long Partnership for Leadership in RNA Therapeutics
Toggle Summary Isis Pharmaceuticals Significantly Improves Upon 2014 Financial Guidance
Toggle Summary Isis Pharmaceuticals Appoints Paula Soteropoulos As President And Chief Executive Officer Of Akcea Therapeutics
Toggle Summary Isis Pharmaceuticals Appoints Sarah Boyce As Chief Business Officer
Toggle Summary Isis Pharmaceuticals Announces Collaboration With Janssen to Discover and Develop RNA-Targeted Therapeutics for Autoimmune Diseases in the GI Tract
Toggle Summary Isis Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Toggle Summary Isis Pharmaceuticals Initiates Phase 1/2 Study of ISIS-DMPK Rx in Patients With Myotonic Dystrophy Type 1
Toggle Summary Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery
Toggle Summary Isis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives Prestigious SCRIP Lifetime Achievement Award
Toggle Summary ISIS-APOCIII Rx Phase 2 Study in Patients With Familial Chylomicronemia Published in the New England Journal of Medicine
Toggle Summary Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Children With Spinal Muscular Atrophy
Toggle Summary ISIS-STAT3 Rx and ISIS-AR Rx Data Presented by AstraZeneca at European Cancer Symposium
Toggle Summary Genzyme and Isis Present KYNAMRO® Clinical Data at the American Heart Association
Toggle Summary Isis Pharmaceuticals to Host Webcast to Discuss ISIS-FXI Rx Data Presented at the ASH Annual Meeting
Toggle Summary Cure SMA Presents Isis Pharmaceuticals with SMA Breakthrough Award